{"id":55867,"date":"2024-02-07T05:43:51","date_gmt":"2024-02-07T05:43:51","guid":{"rendered":"https:\/\/medsname.com\/alphagan-p-drop\/"},"modified":"2026-04-30T10:24:43","modified_gmt":"2026-04-30T10:24:43","slug":"alphagan-p-drop","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/alphagan-p-drop\/","title":{"rendered":"Alphagan P kapky"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Quick Answer \u2014 What is Alphagan P Drop?<\/h3>\n

Alphagan P Drop is brimonidine 0.15%, an alpha-2 adrenergic agonist eye drop that lowers eye pressure ~20% by reducing aqueous production AND increasing uveoscleral outflow. Three times daily dosing. Caution in children \u2014 avoid in age < 2 years (apnoea risk).<\/p>\n<\/div>\n

Pro\u010d objedn\u00e1vat z MedsBase?<\/strong> Dod\u00e1v\u00e1no od v\u00fdrobce certifikovan\u00e9ho WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Doprava po cel\u00e9m sv\u011bt\u011b \u00b7 1 400+ ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Alphagan P Drop is sourced from a WHO-GMP certified manufacturer and shipped worldwide in plain, discreet packaging. Every order is covered by our Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a> \u2014 pokud nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me bez dal\u0161\u00edch n\u00e1klad\u016f. Podpo\u0159eno v\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdmi recenzemi z\u00e1kazn\u00edk\u016f.<\/p>\n

What is Alphagan P Drop?<\/h2>\n

Alphagan P Drop is manufactured by Allergan and contains brimonidine tartrate 0.15% as a sterile ophthalmic solution. Brimonidine is a highly selective alpha-2 adrenergic agonist used to lower IOP in open-angle glaucoma and ocular hypertension. It has a unique dual mechanism \u2014 reducing aqueous humour production AND increasing uveoscleral outflow \u2014 and is one of the few glaucoma drops with a possible neuroprotective effect on retinal ganglion cells suggested by laboratory and small-cohort clinical evidence.<\/p>\n

Jak to funguje<\/h2>\n

Brimonidine activates alpha-2 receptors on the ciliary body, decreasing cAMP and reducing aqueous production. It also increases uveoscleral outflow. Average IOP reduction is 18\u201322%. The 0.15% formulation (Alphagan P) uses a Purite preservative system that breaks down in the tear film into water, oxygen, and chloride ions, making it gentler than benzalkonium chloride for long-term use.<\/p>\n

Indikace & D\u00e1vkov\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n
Indikace<\/th>\nD\u00e1vka<\/th>\n<\/tr>\n<\/thead>\n
Open-angle glaucoma \/ ocular hypertension<\/td>\n1 drop in affected eye(s) three times daily (every 8 hours)<\/td>\n<\/tr>\n
Dopl\u0148kov\u00e1 terapie<\/td>\nDvakr\u00e1t denn\u011b<\/td>\n<\/tr>\n
Post-laser (LPI, SLT) IOP spike prophylaxis<\/td>\n1 drop pre-procedure and 1 drop post-procedure<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
Paediatric apnoea \u2014 avoid in children < 2 years.<\/strong> Brimonidine readily crosses the blood-brain barrier. In children younger than 2, even ophthalmic brimonidine has caused life-threatening CNS depression with apnoea, bradycardia, and hypotension. Avoid in age < 2; use with extreme caution in age 2\u20136 years (Alphagan P 0.1% formulation only, with parental supervision and observation).<\/div>\n

Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n

Local (10\u201320%):<\/strong> conjunctival hyperaemia, allergic conjunctivitis (typically appears at 6\u201318 months \u2014 characteristic late onset), follicular conjunctivitis, eye pruritus, foreign body sensation, blurred vision.<\/p>\n

Syst\u00e9mov\u00e9:<\/strong> dry mouth, fatigue, drowsiness, headache, hypotension. Children (especially under 6) can develop somnolence and bradycardia.<\/p>\n

Varov\u00e1n\u00ed a kontraindikace<\/h2>\n